Role of tiotropium in chronic obstructive pulmonarydisease exacerbation

Pant, P; Yadav, B; Khan, G M; Koju, R; Gurung, R; Pokharel, B; Bedi, T R S; Adkhari, R K

Article:
Role of tiotropium in chronic obstructive pulmonarydisease exacerbation

creativeworkseries.issn	ISSN (Print) : 1993-2979 \| ISSN (Online) : 1993-2987
dc.contributor.author	Pant, P
dc.contributor.author	Yadav, B
dc.contributor.author	Khan, G M
dc.contributor.author	Koju, R
dc.contributor.author	Gurung, R
dc.contributor.author	Pokharel, B
dc.contributor.author	Bedi, T R S
dc.contributor.author	Adkhari, R K
dc.date.accessioned	2026-06-12T06:28:51Z
dc.date.available	2026-06-12T06:28:51Z
dc.date.issued	2010
dc.description	P Pant Department of Internal Medicine, Kathmandu University School of Medical Sciences B Yadav Department of Pharmacy, Kathmandu University, Dhulikhel, Kavre, Nepal R Koju Department of Internal Medicine, Kathmandu University School of Medical Sciences R. Gurung Department of Internal Medicine, Kathmandu University School of Medical Sciences B. Pokharel Department of Internal Medicine, Kathmandu University School of Medical Sciences T.R.S. Bedi Department of Internal Medicine, Kathmandu University School of Medical Sciences R.K. Adhikari Department of Community Medicine, Kathmandu University School of Medical Science
dc.description.abstract	Abstract Introduction: Chronic obstructive pulmonary disease (COPD) remains a major public health problem. Many patients suffering from chronic obstructive lungs diseases are of poor economic status, mostly illiterate, therefore has a direct bearing on patient compliance. Tiotropium is a new anticholinergic therapy for chronic obstructive pulmonary disease that differs from ipratropium by its functional relative selectively for musarinic receptor subtypes and which allows single dosing a day. This study presents a cost-effectiveness, efficacy, and side-effects of Ipratropium bromide and Tiotropium in COPD. Methods: Prospective study was conducted In Kathmandu University Teaching Hospital, between the year 2008 and 2009 in terms of cost-effectiveness, efficacy, and side-effects of Tiotropium and Ipratropium amongst COPD patients. Results: Tiotropium and Ipratropium were prescribed in total of 57 patients (30 in ipratropium bromide and 27 in tiotropium bromide) for the management of COPD among outpatients. There were no significant differences in age, height, weight and baseline lung function parameters (FEV1 and PEF) between the two drugs i.e. ipratropium bromide and tiotropium bromide. Significant improvement in lung function parameters were found in each respective group of drugs after bronchodilator therapy. Tiotropium results in significant reduction of Chronic Obstructive Pulmonary disease exacerbations and significant improvement in quality of life, lung function, and dyspnoea compared to ipratropium. The additional cost to achieve these favorable outcomes was cheaper than Ipratropium bromide. (Nepalese Rs. 7.03 per day for tiotropium as compared to Rs. 9.06 for Ipratropium) Conclusions: Tiotropium results in significant reduction of chronic obstructive pulmonary disease exacerbations and significant improvement in quality of life, lung function and dyspnoea compared to Ipratropium. Keywords: Chronic obstructive pulmonary disease, ipratropium, tiotropium
dc.identifier	https://doi.org/10.59779/jiomnepal.496
dc.identifier.uri	https://hdl.handle.net/20.500.14572/6458
dc.language.iso	en_US
dc.publisher	Institute of Medicine
dc.subject	Chronic obstructive pulmonary disease
dc.subject	ipratropium
dc.subject	tiotropium
dc.title	Role of tiotropium in chronic obstructive pulmonarydisease exacerbation
dc.type	Article
dspace.entity.type	Publication
local.article.type	Original Article
oaire.citation.endPage	10
oaire.citation.startPage	5
relation.isJournalIssueOfPublication	c662af3b-71a7-4ca2-8302-bf48ab1a394c
relation.isJournalIssueOfPublication.latestForDiscovery	c662af3b-71a7-4ca2-8302-bf48ab1a394c
relation.isJournalOfPublication	a9ba45d9-ee33-4a6b-b1fc-6626b87eec6c